Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01194830 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 234
- Enrollment target
NCT01194830 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 234 participants.
The verdict
NCT01194830, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 234 participants
- Enrollment target
Study Summary
Study of linagliptin vs. placebo in Black/African American patients with T2DM with a MTT sub-study
Interventions
- DRUG Placebo
- DRUG Linagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2010-09 |
| Est. Completion | 2011-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01194830
The ClinicalTrials.gov registry entry for NCT01194830 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01194830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01194830 about?
NCT01194830 is a clinical study titled "Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study". Study of linagliptin vs. placebo in Black/African American patients with T2DM with a MTT sub-study
What is the current status of trial NCT01194830?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 234 participants. The study started on 2010-09. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01194830?
The interventions under investigation include: Placebo (DRUG), Linagliptin (DRUG).
Who is sponsoring clinical trial NCT01194830?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.